Abstract: Cyclic peptide compounds are provided having the general formula (I) shown below. The cyclic peptide compounds are also provided for use in the preparation of a pharmaceutical composition for preventing and/or treating stroke, and related conditions or diseases. Experimental data indicate that the cyclic peptide compounds can have a preventive and/or therapeutic effect on stroke, and related conditions/diseases.

Abstract: Novel compounds of formula (II) are disclosed. Compounds of formula (II) comprise ornithine derivatives or compounds that can metabolize under physiological conditions to ornithine. The pH and plasma stability of compounds of formula (II) is also described. Also disclosed are methods for the treatment of neurodegenerative diseases such as Alzheimer's Disease using compounds of formula (II).

Abstract: Described herein are methods for treating PKD in a subject suffering from PKD, the method comprising administering a therapeutically effective amount of at least one compound of the general formula (I), (I) or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein R1-R5 are defined herein.

Abstract: Novel compounds of formula (II) are disclosed. Compounds of formula (II) comprise ornithine derivatives or compounds that can metabolize under physiological conditions to ornithine. The pH and plasma stability of compounds of formula (II) is also described. Also disclosed are methods for the treatment of neurodegenerative diseases such as Alzheimer's Disease using compounds of formula (II).

Abstract: Novel compounds of formula (II) are disclosed. Compounds of formula (II) comprise ornithine derivatives or compounds that may metabolize to ornithine. Also disclosed are methods for the treatment of neurodegenerative diseases such as Alzheimer's Disease using compounds of formula (II).

Abstract: Novel compounds of formula (II) are disclosed. Compounds of formula (II) comprise ornithine derivatives or compounds that can metabolize under physiological conditions to ornithine. The pH and plasma stability of compounds of formula (II) is also described. Also disclosed are methods for the treatment of neurodegenerative diseases such as Alzheimer's Disease using compounds of formula (II).

Abstract: Novel compounds of formula (II) are disclosed. Compounds of formula (II) comprise ornithine derivatives or compounds that may metabolize to ornithine. Also disclosed are methods for the treatment of neurodegenerative diseases such as Alzheimer's Disease using compounds of formula (II).

Abstract: A modified non-human warm-blooded vertebrate animal in which a biologically active human APP polypeptide is expressed, and in which function of its inducible Nitric Oxide Synthase (iNOS) protein is reduced as compared to a non-modified animal, methods of making the animal, and methods of testing a candidate composition for activity in the treatment of Alzheimer's Disease using the animal.

Abstract: A modified non-human warm-blooded vertebrate animal in which a biologically active human APP polypeptide is expressed, and in which function of its inducible Nitric Oxide Synthase (iNOS) protein is reduced as compared to a non-modified animal, methods of making the animal, and methods of testing a candidate composition for activity in the treatment of Alzheimer's Disease using the animal.

Abstract: This application describes a purified and isolated fragment of a nucleic acid molecule encoding an amyloid precursor mutein, wherein the fragment comprises a nucleic acid sequence encoding at least one marker and a nucleic acid sequence of about 419, about 475 or about 494 amino acid residues in which a portion thereof encodes a .beta.-amyloid protein domain. Also described is a method for screening for a compound which reduces the formation of .beta.-amyloid protein.

Abstract: This disclosure concerns a method of detecting the presence of a polypeptide in a sample wherein the polypeptide is encoded by a fragment of a nucleic acid molecule encoding an amyloid precursor mutein and the fragment comprises a sequence encoding at least one marker and a sequence encoding about 419 amino acid residues of the APP-695 isoform, about 475 amino acid residues of the APP-751 isoform or about 494 amino acid residues of the APP-770 isoform. The method encompasses contacting the sample with an antibody, which specifically binds the marker or the amyloid precursor mutein, under suitable conditions to favor the formation of an antibody-antigen complex and detecting the presence of any complex thus formed. The disclosure also deals with the method employing the above nucleic acid fragment wherein the amino acid residues from position 11 to position 28 are deleted from the portion of the sequence encoding the .beta.

Abstract: This application describes a purified and isolated fragment of a nucleic acid molecule encoding an amyloid precursor mutein, wherein the fragment comprises a nucleic acid sequence encoding at least one marker and a nucleic acid sequence of about 419, about 475 or about 494 amino acid residues in which a portion thereof encodes a .beta.-amyloid protein domain. Also described is a method for screening for a compound which reduces the formation of .beta.-amyloid protein.

Abstract: This application describes a purified and isolated fragment of a nucleic acid molecule encoding an amyloid precursor mutein, wherein the fragment comprises a nucleic acid sequence encoding at least one marker and a nucleic acid sequence of about 419, about 475 or about 494 amino acid residues in which a portion thereof encodes a .beta.-amyloid protein domain. Also described is a method for screening for a compound which reduces the formation of .beta.-amyloid protein.